Pretransplant serum FT3 levels in recipients predict early non-relapse mortality after myeloablative allogeneic haematopoietic cell transplantation from matched sibling donors

Figures & data

Table 1. Patient characteristics.

	Total (n = 474)	FT3 <4.7 pmol/l (n = 144)	FT3 ≥4.7 pmol/l (n = 330)	p
Median age, years (range)	36(18–63)	38(19–63)	36(18–58)	0.123
Sex, male/female	271/203	72/72	199/131	<0.041
Diagnosis				0.067
Acute myeloid leukaemia	237	71	166
Acute lymphocytic leukaemia	118	42	76
Myelodysplastic syndrome	49	16	33
Lymphoma	24	9	15
Other	46	6	40
Disease status				0.700
Standard risk	300	93	207
High risk	174	51	123
HCT-CI				0.351
0–2	418	130	288
≥3	56	14	42
Graft type				0.250
BM alone	70	27	43
PBSCs alone	272	77	195
BM + PBSCs	132	40	92
Donor				0.064
Matched sibling	219	72	147
Unrelated	119	26	93
Haplo-identical	136	46	90
Conditioning regimen				0.215
Bu/Cy	425	125	299
TBI/Cy	49	19	31

Notes: FT3: free triiodothyronine 3; HCT-CI: haematopoietic cell transplantation comorbidity index; BM: bone marrow; PBSCs: peripheral blood stem cells; Bu: busulfan; Cy: cyclophosphamide; TBI: total body irradiation.

Figure 1. ROC to evaluate the value of the baseline serum FT3 level for predicting early NRM after transplantation.

Figure 2. Cumulative incidences of early NRM within 100 days (a) and NRM at 3 years (b) according to the baseline serum FT3 level.

Figure 3. The probability of the 3-year OS according to the baseline serum FT3 level.

Table 2. Univariate and multivariate analysis of early NRM.

	n	100-day NRM (95% CI)	Univariate p-value	Hazard ratio (95% CI)	Multivariate p-value
Age
<41	101	6 (3–9)%	0.246
≥41	118	10 (7–13)%
Sex
Male	118	9 (6–12)%	0.548
Female	101	7 (4–10)%
Diagnosis
Acute leukaemia	158	8 (6–10)%	0.573
Other	61	10 (6–14)%
Disease status
Standard risk	136	7 (5–9)%	0.257
High risk	83	11 (8–14)%
HCT-CI
0–2	190	7 (5–9)%	0.049	1	0.121
≥3	29	17 (10–24)%		2.59 (0.78–8.59)
Graft type
BM alone	47	4 (1–7)%	0.527
PBSCs alone	122	9 (6–12)%
BM + PBSCs	50	10 (6–14)%
Conditioning
Bu/Cy	195	8 (6–10)%	0.933
TBI/Cy	24	8 (2–14)%
FT3
<4.2 pmol/l	72	14 (10–18)%	0.033	3.19 (1.13–9.03)	0.029
≥4.2 pmol/l	147	6 (4–8)%		1

Figure 4. Suggested algorithm for patients undergoing sibling HCT.